Showing results (371-380 of 1,017) with videos related to

Sort By:
Pageof 102
British Journal of Haematology|September 15, 2009
Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemiaFranco Locatelli, Anna M Testi, Maria Ester Bernardo, et al.
American Journal of Medical Genetics. Part A|April 12, 2023
First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosisLucia Santoro, Chiara Monachesi, Lucia Zampini, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|October 25, 2023
CD72 is a pan-tumor antigen associated to pediatric acute leukemiaBarbara Buldini, Giovanni Faggin, Elena Porcù, et al.
Blood|July 27, 2006
Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemiaDaniela Montagna, Rita Maccario, Franco Locatelli, et al.
Blood|February 7, 2004
T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantationDaniela Montagna, Franco Locatelli, Antonia Moretta, et al.
Frontiers in Immunology|May 23, 2019
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell KillingTiziano Ingegnere, Francesca Romana Mariotti, Andrea Pelosi, et al.
Oncology Reports|January 5, 2006
Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemiaGeertruy Te Kronnie, Silvio Bicciato, Lisa Franceschini, et al.
Blood|May 1, 2009
Imatinib for refractory chronic graft-versus-host disease with fibrotic featuresAttilio Olivieri, Franco Locatelli, Marco Zecca, et al.
Pediatric Blood & Cancer|July 22, 2009
Congenital aggressive variant of Langerhans cells histiocytosis with CD56+/E-Cadherin- phenotypeMarco Lucioni, Giampiero Beluffi, Laura Bandiera, et al.
Oncoimmunology|July 7, 2017
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastomaElisa Brandetti, Irene Veneziani, Ombretta Melaiu, et al.
Pageof 102